

Appendix

Potential target patient populations 2021

Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience


Immunology

Herceptin + Perjeta, Tecentriq: *HER2+ early Breast Cancer (eBC)*




Source: Roche/Genentech

Perjeta, Herceptin, Kadcylla, Tecentriq: HER2+ metastatic Breast Cancer (mBC)




	Adjuvant Relapse	de novo
1L Patients (Top 5 EU)	5,300	3,800
1L Patients (US)	5,700	4,100
	HER2+ Rx opportunities Drug treated patients	
	US	5 EU
1L	5,700	5,300
2L	6,300	7,700

Ipatasertib, Giredestrant: HER2-/HR+ 1L and recurrent mBC




Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; Ipatasertib in collaboration with Array BioPharma

Tecentriq, Ipatasertib: Triple Negative Breast Cancer (TNBC)




Tecentriq:


Adjuvant squamous cell carcinoma of the head and neck (SCCHN)




Tecentriq, Tiragolumab: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC)




Rozlytrek (ROS1+) and Gavreto (RET+): *ROS1+ or RET+ metastatic non-small cell lung cancer (mNSCLC)*




Alecensa: ALK+ Non Small Cell Lung Cancer (NSCLC)



Tecentriq, Tiragolumab: Small Cell Lung Cancer (SCLC)




Tecentriq, Zelboraf: 1L BRAF+ metastatic Melanoma (mM)




Tecentriq:


Metastatic Urothelial Bladder Cancer (mUBC)




Tecentriq: *NIMBC/ MIBC*



Tecentriq: Renal Cell Carcinoma (RCC)




Tecentriq: Hepatic Cell Carcinoma (HCC)




Tiragolumab:

Esophageal squamous cell carcinoma (ESCC)




Ipatasertib:


Metastatic castration-resistant prostate cancer (mCRPC)




Gazyva, Rituxan, Monsunetuzumab, Glofitamab: Indolent Non-Hodgkin's Lymphoma (iNHL)




Polivy, Rituxan, Monsunetuzumab, Glofitamab: Aggressive Non-Hodgkin's Lymphoma (aNHL/DLBCL)



Gazyva, Venclexta, Rituxan: Chronic Lymphocytic Leukemia (CLL)




Venclexta: Acute Myeloid Leukemia (AML)



Source: Roche/Genentech; Venclexta in collaboration with AbbVie

Venclexta: Multiple Myeloma (MM)



Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Hemlibra: *Hemophilia A*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Faricimab, Port Delivery System (PDS), Lucentis: *Age-related Macular Degeneration (AMD)*




Faricimab, Port Delivery System (PDS), Lucentis: *Diabetic Macular Edema (DME)*



Port Delivery System (PDS), Lucentis: *Retinal Vein Occlusion (RVO)*



RG6312, RG6147, RG6299*: *Geographic Atrophy (GA)*



Source: Roche/Genentech; * Study conducted by Ionis, Roche has option to in-license

Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Xofluza: Influenza A & B



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Ocrevus, Fenebrutinib: Multiple Sclerosis (MS)




Evrysdi: *Spinal Muscular Atrophy (SMA)*




Myostatin inhibiting adnectin fusion protein (RG6206): *Duchenne Muscular Dystrophy (DMD)*




Tominersen (HTT-ASO, RG6042): *Huntington's Disease (HD)*




Gantenerumab, Semorinemab: *Alzheimer's Disease (AD)*




Enspryng: *Neuromyelitis Optica Spectrum Disorder (NMOSD)*



Prasinezumab (RG7935): *Parkinson's Disease (PD)*



Crovalimab (RG6107, SKY59): *Paroxysmal Nocturnal Hemoglobinuria (PNH)*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology

Pentraxin-2, Esbriet: *Idiopathic Pulmonary Fibrosis (IPF)*




Diagnosed Prevalence by Severity




Xolair:

Moderate to severe Asthma



Xolair:



Nasal Polyps / Chronic idiopathic urticarial (CIU) / Food allergy




Actemra, Rituxan: Rheumatoid Arthritis (RA)

Global target population for Actemra and Rituxan in rheumatoid arthritis is ~1.3M biologics eligible patients.

US Biologic treated patients by line of therapy




Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA)




Actemra:


Polyarticular Juvenile Idiopathic Arthritis (pJIA)




Actemra: Giant Cell Arteritis (GCA)



Etrolizumab: *Crohn's Disease (CD)*



Gazyva: *Lupus Nephritis (LN)*



Doing now what patients need next